Home Blog Page 2
UTC Laboratories—also known as Renaissance RX (RenRX)—and its three principals have agreed to pay a combined $42.6 million to settle federal allegations that they paid kickbacks in exchange for laboratory referrals for pharmacogenetic testing, as well as for furnishing and billing for tests that were not medically necessary, all in violation of the False Claims Act. In addition, New Orleans-based...
Provista Diagnostics researchers say the company's Videssa® Breast test can help inform better decision-making after abnormal mammogram or other breast imaging results and potentially reduce the use of traditional biopsy by up to 67%. (Source: [iStock/David Marchal)
Salk Institute researchers have used of a state-of-the-art technology known as single-nucleus (sn) assay for transposase-accessible chromatin (ATAC) sequencing (snATAC-seq) to profile how specific types of mammary cells differentiate during development. The findings, published in Cell Reports, provide new insights into normal breast development, and could ultimately point to new therapeutic strategies for different subtypes of breast cancer. The...
Novartis is soliciting proposals from patient advocacy organizations for initiatives designed to expand and improve understanding of biomarker testing among people with cancer that are based on the pharma giant’s Solutions to Empower Patients (STEP) Program. The STEP Program will fund up to four patient advocacy organizations as much as $75,000 each, with the aim of helping them address education,...
Next-Generation Sequencing Test for Cutaneous Melanoma
Investigators at the Moffitt Cancer Center’s Donald A. Adam Melanoma and Skin Cancer Center of Excellence have just released findings from a new study revealing that differences at the single-cell level can predict responses to initial BRAF inhibitor therapy and that leveraging these differences may improve patient outcomes. Patients with advanced melanoma have been able to live longer because...
digital dna
The volume of information that needs to be analyzed to make precision medicine a reality in cancer care is often beyond the realm of the human mind. That’s where artificial intelligence steps in
Invitae lab
Among the challenges long faced by diagnostics developers striving to broaden the use of their tests is finding enough patients to generate enough samples, especially for rare or inherited disorders, as well as finding ways of getting paid for that testing. Invitae launched its own solution to those challenges in July, when it announced it is offering, without charge to...
With NGS diagnostics
Two leaders in genomics and molecular analysis, Illumina and QIAGEN, have announced a 15-year partnership that the companies say is aimed at increasing the availability and use of NGS-based in-vitro diagnostics (IVDs) for precision medicine applications. Under the terms of the agreement, Qiagen has received non-exclusive right to develop and commercialize diagnostic kits to used on Illumina’s MiSeq Dx and...
Centogene’s CentoMD® rare disease variant database will be integrated into Qiagen’s bioinformatics suite in a rare disease bioinformatics collaboration by the companies. [Source: alengo/Getty]
About $31 million in grants has been awarded by The National Institutes of Health in fiscal year 2019 to 20 teams in order to increase the percentage of treatments for rare diseases. Awardees include five new groups of scientists, clinicians, patients, families and patient advocates representing a wide range of rare diseases. An additional $7 million has been awarded...
Stomach Ache Problem
Prometheus Biosciences said its bioinformatics platform and advanced machine learning techniques will be used by Takeda Pharmaceutical as part of a global collaboration to develop up to three targeted inflammatory bowel disease (IBD) therapeutics with companion diagnostics. The collaboration could generate up to $420 million for Prometheus in development, regulatory, and commercial milestone payments across all three programs, in addition...
DNA Test Sanger Sequencing
Leveraging improvements in sequencing technology that increase speed and lower costs, rare disease diagnostics broadens its reach.
Scroll Up